10-Q 1 srzn-20220930.htm 10-Q 10-Q
Q30001824893--12-31falseSurrozen, Inc./DE0001824893us-gaap:RetainedEarningsMember2022-06-300001824893srzn:WarrantToPurchaseCommonStockMember2021-01-012021-09-300001824893us-gaap:FairValueMeasurementsRecurringMember2022-09-3000018248932021-01-012021-09-300001824893srzn:PublicWarrantsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001824893srzn:CorporateBondMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001824893srzn:EighteenMonthsMember2020-01-3100018248932022-04-012022-06-300001824893srt:ScenarioForecastMember2022-11-012022-11-300001824893us-gaap:CommonStockMember2022-09-300001824893srzn:CorporateBondMember2022-09-300001824893us-gaap:FairValueInputsLevel2Membersrzn:PublicWarrantsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001824893srzn:DistributedBioSubscriptionAgreementMembersrzn:StanfordMember2022-07-012022-09-300001824893us-gaap:AdditionalPaidInCapitalMember2022-04-012022-06-300001824893srzn:ClosingSalePriceBelow1000PerShareMembersrzn:LincolnParkMember2022-02-280001824893srt:MaximumMembersrzn:LincolnParkMember2022-02-012022-02-280001824893srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberus-gaap:CommonStockMember2020-12-310001824893srzn:CommonStock1Membersrzn:PrivatePlacementWarrantsMember2022-09-300001824893us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001824893us-gaap:RetainedEarningsMember2022-09-300001824893us-gaap:FairValueInputsLevel2Membersrzn:PIPEWarrantsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001824893us-gaap:RetainedEarningsMember2021-03-310001824893us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001824893stpr:CAsrzn:EightYearsMember2022-09-300001824893srt:MaximumMember2022-02-012022-02-280001824893srzn:UnvestedCommonStockSharesSubjectToRepurchaseMember2021-01-012021-09-300001824893us-gaap:CommonStockMember2021-06-300001824893us-gaap:SubsequentEventMember2022-10-012022-12-310001824893us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001824893srzn:PublicWarrantsMembersrzn:CommonStock2Member2022-09-300001824893us-gaap:CommonStockMember2021-01-012021-03-3100018248932022-03-310001824893srzn:DistributedBioSubscriptionAgreementMembersrzn:StanfordMember2022-01-012022-09-300001824893srt:MaximumMembersrzn:LincolnParkMember2022-02-280001824893us-gaap:FairValueInputsLevel1Membersrzn:GovernmentBondsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001824893us-gaap:AdditionalPaidInCapitalMember2020-12-310001824893srzn:LincolnParkMember2022-02-012022-02-280001824893srzn:PrivatePlacementWarrantsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001824893us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001824893us-gaap:CommonStockMember2022-01-012022-03-310001824893us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001824893us-gaap:EmployeeStockMembersrzn:TwoThousandTwentyOneStockPlanMember2022-01-012022-09-300001824893srzn:PublicWarrantsMember2022-01-012022-09-3000018248932022-09-300001824893us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember2021-07-012021-09-300001824893us-gaap:CommercialPaperMember2021-12-310001824893srzn:UCSFLicenseAndOptionAgreementsMembersrzn:StanfordMember2022-01-012022-09-300001824893us-gaap:AdditionalPaidInCapitalMember2021-06-300001824893srzn:PrivateInvestmentInPublicEntityOfferingMember2021-08-110001824893srzn:PIPEWarrantsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001824893srzn:GovernmentBondsMember2021-12-310001824893us-gaap:FairValueInputsLevel2Membersrzn:PublicWarrantsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001824893us-gaap:FairValueInputsLevel2Membersrzn:GovernmentBondsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001824893srzn:PrivateInvestmentInPublicEntityOfferingMember2021-08-012021-08-3100018248932022-01-012022-03-310001824893us-gaap:FairValueInputsLevel3Membersrzn:GovernmentBondsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001824893us-gaap:FairValueInputsLevel1Membersrzn:PrivatePlacementWarrantsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001824893us-gaap:EmployeeStockOptionMember2021-01-012021-09-300001824893us-gaap:RetainedEarningsMember2021-07-012021-09-300001824893us-gaap:CommonStockMember2022-06-300001824893us-gaap:SubsequentEventMembersrzn:TwoThousandTwentyOneStockPlanMember2022-10-012022-10-310001824893us-gaap:FairValueInputsLevel1Membersrzn:PublicWarrantsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001824893us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMembersrt:ScenarioPreviouslyReportedMember2020-12-3100018248932021-01-012021-12-310001824893us-gaap:AdditionalPaidInCapitalMembersrt:RevisionOfPriorPeriodReclassificationAdjustmentMember2020-12-310001824893us-gaap:AdditionalPaidInCapitalMember2022-06-300001824893us-gaap:SubsequentEventMembersrzn:TwoThousandTwentyOneStockPlanMember2022-10-310001824893us-gaap:CommonStockMember2020-12-310001824893srt:MinimumMembersrzn:LincolnParkMember2022-02-012022-02-280001824893us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300001824893srzn:ForeignBondsMember2021-12-310001824893srzn:RestrictedStockAwardRSAMember2022-01-012022-09-300001824893us-gaap:FairValueInputsLevel2Membersrzn:GovernmentBondsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001824893srzn:PrivatePlacementWarrantsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001824893us-gaap:StockOptionMember2022-07-012022-09-3000018248932020-01-012020-01-310001824893us-gaap:FairValueInputsLevel2Membersrzn:PrivatePlacementWarrantsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001824893us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember2022-04-012022-06-300001824893us-gaap:SubsequentEventMembersrzn:RegentsUniversityMember2022-11-012022-11-300001824893srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberus-gaap:RedeemablePreferredStockMember2020-12-310001824893us-gaap:FairValueInputsLevel1Membersrzn:GovernmentBondsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-3000018248932021-07-012021-09-300001824893us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-3000018248932021-01-012021-03-310001824893srzn:PublicWarrantsMembersrzn:CommonStock2Member2022-01-012022-09-300001824893us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember2022-07-012022-09-300001824893srzn:PublicWarrantsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001824893us-gaap:RedeemablePreferredStockMembersrt:ScenarioPreviouslyReportedMember2020-12-310001824893srt:RevisionOfPriorPeriodReclassificationAdjustmentMember2020-12-310001824893srzn:ForeignBondsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001824893srzn:StanfordLicenseAgreementsMembersrzn:StanfordMember2016-03-012016-03-310001824893us-gaap:FairValueInputsLevel2Membersrzn:PIPEWarrantsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001824893us-gaap:RetainedEarningsMember2021-12-310001824893srzn:ForeignBondsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001824893srzn:UnvestedCommonStockSharesSubjectToRepurchaseMember2022-01-012022-09-300001824893srzn:PublicWarrantsMembersrzn:CommonStock1Member2022-09-3000018248932020-12-310001824893us-gaap:RetainedEarningsMember2021-04-012021-06-300001824893us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001824893us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001824893srzn:RedeemableWarrantMember2022-01-012022-09-300001824893us-gaap:CommonStockMember2021-03-310001824893us-gaap:RetainedEarningsMember2022-04-012022-06-300001824893us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001824893srzn:WarrantToPurchaseCommonStockMember2022-01-012022-09-300001824893srzn:PrivateInvestmentInPublicEntityOfferingMember2022-01-012022-09-300001824893us-gaap:StockOptionMember2021-01-012021-09-300001824893us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001824893us-gaap:EmployeeStockMembersrt:MaximumMembersrzn:TwoThousandTwentyOneStockPlanMember2022-01-012022-09-300001824893us-gaap:RetainedEarningsMember2022-03-310001824893srzn:CorporateBondMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001824893srzn:EmployeeStockPurchasePlanMember2022-01-012022-09-300001824893us-gaap:FairValueInputsLevel1Membersrzn:PublicWarrantsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001824893stpr:CAsrzn:EightYearsMember2016-08-310001824893srzn:CorporateBondMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001824893us-gaap:RetainedEarningsMember2022-07-012022-09-300001824893srt:MaximumMembersrzn:ClosingSalePriceBelow1000PerShareMember2022-02-280001824893us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember2021-12-310001824893us-gaap:RetainedEarningsMember2022-01-012022-03-310001824893us-gaap:FairValueInputsLevel1Membersrzn:PIPEWarrantsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001824893srt:ScenarioPreviouslyReportedMember2020-12-310001824893us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001824893srzn:ClosingSalePriceBelow1200PerShareMember2022-02-280001824893us-gaap:SubsequentEventMember2022-10-3100018248932021-04-012021-06-300001824893us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300001824893us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001824893us-gaap:FairValueInputsLevel3Membersrzn:PrivatePlacementWarrantsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001824893us-gaap:CommonStockMember2022-07-012022-09-300001824893us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001824893srzn:RestrictedStockAwardRSAMember2022-01-012022-09-300001824893us-gaap:GeneralAndAdministrativeExpenseMember2022-07-012022-09-300001824893us-gaap:AdditionalPaidInCapitalMember2022-03-310001824893us-gaap:FairValueInputsLevel2Membersrzn:CorporateBondMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001824893us-gaap:FairValueInputsLevel1Membersrzn:PrivatePlacementWarrantsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001824893us-gaap:CommercialPaperMember2022-09-300001824893us-gaap:RetainedEarningsMember2021-09-300001824893srzn:ForeignBondsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001824893us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember2022-06-300001824893us-gaap:FairValueInputsLevel3Membersrzn:GovernmentBondsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001824893srzn:PrivateInvestmentInPublicEntityOfferingMember2021-08-310001824893us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300001824893us-gaap:RetainedEarningsMembersrt:ScenarioPreviouslyReportedMember2020-12-310001824893srzn:RestrictedStockAwardRSAMember2021-01-012021-09-300001824893us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001824893srzn:DistributedBioSubscriptionAgreementMember2016-09-012016-09-300001824893us-gaap:AdditionalPaidInCapitalMember2021-03-310001824893srzn:RestrictedStockAwardRSAMember2022-09-300001824893us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember2022-03-310001824893srzn:PIPEWarrantsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001824893us-gaap:FairValueInputsLevel2Membersrzn:PrivatePlacementWarrantsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001824893us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-3000018248932022-01-012022-09-300001824893us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001824893srzn:RestrictedStockAwardRSAMember2021-12-310001824893us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001824893us-gaap:FairValueInputsLevel2Membersrzn:ForeignBondsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001824893us-gaap:FairValueInputsLevel2Membersrzn:CorporateBondMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001824893srzn:SurrozenIncMember2021-08-310001824893us-gaap:FairValueInputsLevel3Membersrzn:PIPEWarrantsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-3100018248932022-11-100001824893us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300001824893us-gaap:CommercialPaperMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001824893srzn:PublicWarrantsMember2022-09-300001824893srzn:PrivatePlacementWarrantsMember2022-09-300001824893us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300001824893srzn:CorporateBondMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001824893srzn:EmployeeStockPurchasePlanMember2022-09-300001824893us-gaap:MeasurementInputExpectedDividendRateMembersrzn:PIPEWarrantsMember2022-09-300001824893us-gaap:CommonStockMember2021-07-012021-09-300001824893us-gaap:FairValueInputsLevel1Membersrzn:PIPEWarrantsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001824893us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300001824893us-gaap:GeneralAndAdministrativeExpenseMember2021-07-012021-09-300001824893us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001824893srzn:CorporateBondMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-3000018248932021-03-310001824893srzn:PublicWarrantsMembersrzn:CommonStock1Member2022-01-012022-09-300001824893us-gaap:CommonStockMember2022-04-012022-06-3000018248932022-07-012022-09-300001824893srzn:LincolnParkMember2022-01-012022-09-300001824893srzn:ClosingSalePriceBelow1200PerShareMembersrt:MaximumMember2022-02-2800018248932022-06-3000018248932021-06-3000018248932021-09-300001824893us-gaap:RetainedEarningsMember2021-06-3000018248932021-08-012021-08-310001824893us-gaap:SubsequentEventMember2022-10-012022-10-310001824893us-gaap:SubsequentEventMembersrzn:StanfordMember2022-11-012022-11-300001824893us-gaap:SubsequentEventMember2023-01-012023-06-300001824893us-gaap:CommonStockMember2021-12-310001824893us-gaap:RetainedEarningsMember2020-12-310001824893srzn:StanfordLicenseAgreementsMembersrzn:StanfordMember2022-01-012022-09-300001824893srzn:LincolnParkMember2022-02-280001824893srt:MaximumMembersrzn:StanfordLicenseAgreementsMembersrzn:StanfordMember2016-03-012016-03-310001824893us-gaap:FairValueInputsLevel3Membersrzn:PIPEWarrantsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001824893srzn:TwoThousandTwentyOneStockPlanMember2022-09-300001824893us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember2022-09-300001824893srzn:CorporateBondMember2021-12-310001824893us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001824893us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001824893us-gaap:EmployeeStockOptionMember2022-01-012022-09-300001824893us-gaap:AdditionalPaidInCapitalMember2021-04-012021-06-300001824893us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001824893srzn:PrivatePlacementWarrantsMember2022-01-012022-09-300001824893us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember2021-09-300001824893srzn:LincolnParkMember2022-09-300001824893us-gaap:AdditionalPaidInCapitalMember2021-09-300001824893srzn:PublicWarrantsMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001824893srzn:GovernmentBondsMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300001824893us-gaap:FairValueInputsLevel3Membersrzn:PublicWarrantsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-3100018248932021-12-310001824893us-gaap:StockOptionMember2022-01-012022-09-300001824893us-gaap:CommonStockMember2022-03-310001824893us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-09-3000018248932021-08-310001824893srzn:PrivateInvestmentInPublicEntityOfferingMember2021-08-112021-08-110001824893us-gaap:FairValueMeasurementsRecurringMember2021-12-310001824893us-gaap:StockOptionMember2021-07-012021-09-300001824893us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-09-300001824893us-gaap:AdditionalPaidInCapitalMember2022-09-300001824893us-gaap:CommonStockMember2021-09-300001824893srzn:GovernmentBondsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001824893us-gaap:CommonStockMember2022-01-012022-09-300001824893us-gaap:AdditionalPaidInCapitalMembersrt:ScenarioPreviouslyReportedMember2020-12-310001824893srt:MinimumMembersrzn:PIPEWarrantsMember2022-01-012022-09-300001824893srzn:StanfordLicenseAgreementsMembersrzn:StanfordMember2018-06-012018-06-300001824893srzn:PIPEWarrantsMember2022-09-300001824893srzn:PIPEWarrantsMember2022-01-012022-09-300001824893us-gaap:FairValueInputsLevel3Membersrzn:PrivatePlacementWarrantsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001824893us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001824893srzn:CorporateBondMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001824893srzn:CommonStock2Membersrzn:PrivatePlacementWarrantsMember2022-09-300001824893us-gaap:AccumulatedOtherComprehensiveIncomeLossDerivativeQualifyingAsHedgeExcludedComponentIncludingPortionAttributableToNoncontrollingInterestMember2022-01-012022-03-310001824893us-gaap:CommonStockMember2021-04-012021-06-300001824893us-gaap:RetainedEarningsMember2021-01-012021-03-310001824893srt:MaximumMembersrzn:PIPEWarrantsMember2022-01-012022-09-300001824893srzn:GovernmentBondsMember2022-09-300001824893srt:ScenarioPreviouslyReportedMemberus-gaap:CommonStockMember2020-12-310001824893us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310001824893us-gaap:AdditionalPaidInCapitalMember2021-12-31xbrli:pureutr:sqftxbrli:sharesiso4217:USDxbrli:sharessrzn:Investmentsiso4217:USD

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, DC 20549

 

FORM 10-Q

 

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2022

OR

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-39635

 

Surrozen, Inc.

(Exact Name of Registrant as Specified in its Charter)

 

 

Delaware

98-1556622

( State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer
Identification No.)

171 Oyster Point Blvd, Suite 400, South San Francisco, California

94080

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (650) 489-9000

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange on which registered

Common Stock, $0.0001 par value per share

 

SRZN

 

The Nasdaq Capital Market

Redeemable warrants, each whole warrant exercisable for one share of Common Stock

 

SRZNW

 

The Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

Large accelerated filer

 

 

Accelerated filer

 

 

 

 

 

Non-accelerated filer

 

 

Smaller reporting company

 

 

 

 

 

 

 

 

Emerging growth company

 

 

 

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No

As of November 10, 2022, there were 35,122,863 shares of common stock, par value $0.0001 per share, issued and outstanding.

 

 


 

Table of Contents

 

 

 

Page

PART I.

FINANCIAL INFORMATION

 

Item 1.

Financial Statements

1

 

Unaudited Condensed Consolidated Balance Sheets as of September 30, 2022 and December 31, 2021

1

 

Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2022 and 2021

2

 

Unaudited Condensed Consolidated Statements of Stockholders’ Equity for the three and nine months ended September 30, 2022

3

 

Unaudited Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity for the three and nine months ended September 30, 2021

4

 

Unaudited Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2022 and 2021

5

 

Notes to Unaudited Condensed Consolidated Financial Statements

6

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

18

Item 3.

Quantitative and Qualitative Disclosures About Market Risk

27

Item 4.

Controls and Procedures

27

 

 

 

PART II.

OTHER INFORMATION

 

Item 1.

Legal Proceedings

29

Item 1A.

Risk Factors

29

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

44

Item 3.

Defaults Upon Senior Securities

44

Item 4.

Mine Safety Disclosures

44

Item 5.

Other Information

44

Item 6.

Exhibits

45

Signatures

46

 

 

i


 

 

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

 

Some of the statements contained in this Report constitute forward-looking statements within the meaning of the federal securities laws. Forward-looking statements relate to expectations, beliefs, projections, future plans and strategies, anticipated events or trends and similar expressions concerning matters that are not historical facts. These forward-looking statements include statements about future financial and operating results of Surrozen; statements about the plans, strategies and objectives of management for future operations of Surrozen; and statements regarding future performance. In some cases, you can identify these forward-looking statements by the use of terminology such as “outlook,” “believes,” “expects,” “potential,” “continues,” “may,” “will,” “should,” “could,” “seeks,” “approximately,” “predicts,” “intends,” “plans,” “estimates,” “anticipates” or the negative version of these words or other comparable words or phrases.

 

These statements are based upon information available to us as of the date of this Report, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and such statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain and investors are cautioned not to unduly rely upon these statements. Except to the extent required by applicable law, we are under no obligation (and expressly disclaim any such obligation) to update or revise our forward-looking statements whether as a result of new information, future events, or otherwise.
 

There are no guarantees that the transactions and events described will happen as described (or that they will happen at all). The forward-looking statements contained in this Report are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances that may cause our actual results to differ significantly from those expressed in any forward-looking statement. For a further discussion of these and other factors that could cause the our future results, performance or transactions to differ significantly from those expressed in any forward-looking statement, please see the section of this Report titled “Risk Factors” and “Item 1A. Risk Factors” of our Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC on March 28, 2022.

ii


 

PART I—FINANCIAL INFORMATION

Item 1. Financial Statements

SURROZEN, INC.

Condensed Consolidated Balance Sheets

(In thousands, except per share amounts)

 

 

 

September 30,
2022

 

 

December 31,
2021

 

 

 

(Unaudited)

 

 

 

 

Assets

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

Cash and cash equivalents

 

$

25,531

 

 

$

33,091

 

Short-term marketable securities

 

 

52,864

 

 

 

68,760

 

Prepaid expenses and other current assets

 

 

4,324

 

 

 

3,338

 

Total current assets

 

 

82,719

 

 

 

105,189

 

 

 

 

 

 

 

 

Property and equipment, net

 

 

3,906

 

 

 

4,794

 

Operating lease right-of-use assets

 

 

3,558

 

 

 

4,582

 

Long-term marketable securities

 

 

 

 

 

21,655

 

Restricted cash

 

 

405

 

 

 

405

 

Other assets

 

 

846

 

 

 

549

 

Total assets

 

$

91,434

 

 

$

137,174

 

 

 

 

 

 

 

 

Liabilities and stockholders’ equity

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

Accounts payable

 

$

362

 

 

$

2,718

 

Accrued and other liabilities

 

 

6,133

 

 

 

8,662

 

Lease liabilities, current portion

 

 

2,159

 

 

 

2,193

 

Total current liabilities

 

 

8,654

 

 

 

13,573

 

 

 

 

 

 

 

 

Lease liabilities, noncurrent portion

 

 

3,957

 

 

 

5,600

 

Warrant liabilities

 

 

1,332

 

 

 

8,301

 

Total liabilities

 

 

13,943

 

 

 

27,474

 

 

 

 

 

 

 

 

Commitments and contingencies (Note 7)

 

 

 

 

 

 

 

 

 

 

 

 

 

Stockholders’ equity:

 

 

 

 

 

 

Preferred stock, $0.0001 par value, 10,000 shares authorized; no shares
   issued and outstanding as of September 30, 2022 and December 31, 2021

 

 

 

 

 

 

Common stock, $0.0001 par value, 500,000 shares authorized as of
   September 30, 2022 and December 31, 2021;
35,123 and 35,034
   shares issued and outstanding as of September 30, 2022 and
   December 31, 2021, respectively

 

 

4

 

 

 

4

 

Additional paid-in capital

 

 

255,789

 

 

 

252,464

 

Accumulated other comprehensive loss

 

 

(424

)

 

 

(119

)

Accumulated deficit

 

 

(177,878

)

 

 

(142,649

)

Total stockholders’ equity

 

 

77,491

 

 

 

109,700

 

Total liabilities and stockholders’ equity

 

$

91,434

 

 

$

137,174

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

1


 

SURROZEN, INC.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(Unaudited)

(In thousands, except per share amounts)

 

 

 

Three Months Ended September 30,

 

 

Nine Months Ended September 30,

 

 

 

 

2022

 

 

2021

 

 

2022

 

 

2021

 

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

$

8,624

 

 

$

10,418

 

 

$

27,576

 

 

$

29,284

 

 

General and administrative

 

 

4,981

 

 

 

3,287

 

 

 

14,594

 

 

 

10,112

 

 

Total operating expenses

 

 

13,605

 

 

 

13,705

 

 

 

42,170

 

 

 

39,396

 

 

Loss from operations

 

 

(13,605

)

 

 

(13,705

)

 

 

(42,170

)

 

 

(39,396

)

 

Interest income

 

 

198

 

 

 

14

 

 

 

307

 

 

 

30

 

 

Other income (expense), net

 

 

50

 

 

 

(328

)

 

 

6,634

 

 

 

(328

)

 

Net loss

 

 

(13,357

)

 

 

(14,019

)

 

 

(35,229

)

 

 

(39,694

)

 

Unrealized gain (loss) on marketable securities, net of tax

 

 

52

 

 

 

(16

)

 

 

(305

)

 

 

(16

)

 

Comprehensive loss

 

$

(13,305

)

 

$

(14,035

)

 

$

(35,534

)

 

$

(39,710

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net loss per share attributable to common
   stockholders, basic and diluted

 

$

(0.38

)

 

$

(0.51

)

 

$

(1.01

)

 

$

(1.86

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Weighted-average shares used in computing net
   loss per share attributable to common
   stockholders, basic and diluted

 

 

34,968

 

 

 

27,402

 

 

 

34,926

 

 

 

21,291

 

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

2


 

SURROZEN, INC.

Condensed Consolidated Statements of Stockholders’ Equity

(Unaudited)

(In thousands)

 

 

 

 

 

 

 

 

 

Additional

 

 

Accumulated
other

 

 

 

 

 

Total

 

 

 

Common stock

 

 

paid-in

 

 

comprehensive

 

 

Accumulated

 

 

stockholders’

 

 

 

Shares

 

 

Amount

 

 

capital

 

 

loss

 

 

deficit

 

 

equity

 

Balance at December 31, 2021

 

 

35,034

 

 

$

4

 

 

$

252,464

 

 

$

(119

)

 

$

(142,649

)

 

$

109,700

 

Issuance of common stock under Equity
   Purchase Agreement

 

 

100

 

 

 

 

 

 

273

 

 

 

 

 

 

 

 

 

273

 

Repurchase of early exercised stock options

 

 

(8

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Vesting of early exercised stock options

 

 

 

 

 

 

 

 

30

 

 

 

 

 

 

 

 

 

30

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

916

 

 

 

 

 

 

 

 

 

916

 

Other comprehensive loss

 

 

 

 

 

 

 

 

 

 

 

(310

)

 

 

 

 

 

(310

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(7,947

)

 

 

(7,947

)

Balance at March 31, 2022

 

 

35,126

 

 

 

4

 

 

 

253,683

 

 

 

(429

)

 

 

(150,596

)

 

 

102,662

 

Repurchase of early exercised stock options

 

 

(2

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Vesting of early exercised stock options

 

 

 

 

 

 

 

 

27

 

 

 

 

 

 

 

 

 

27

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

979

 

 

 

 

 

 

 

 

 

979

 

Other comprehensive loss

 

 

 

 

 

 

 

 

 

 

 

(47

)

 

 

 

 

 

(47

)

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(13,925

)

 

 

(13,925

)

Balance at June 30, 2022

 

 

35,124

 

 

 

4

 

 

 

254,689

 

 

 

(476

)

 

 

(164,521

)

 

 

89,696

 

Repurchase of early exercised stock options

 

 

(1

)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Vesting of early exercised stock options

 

 

 

 

 

 

 

 

23

 

 

 

 

 

 

 

 

 

23

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

1,077

 

 

 

 

 

 

 

 

 

1,077

 

Other comprehensive income

 

 

 

 

 

 

 

 

 

 

 

52

 

 

 

 

 

 

52

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(13,357

)

 

 

(13,357

)

Balance at September 30, 2022

 

 

35,123

 

 

$

4

 

 

$

255,789

 

 

$

(424

)

 

$

(177,878

)

 

$

77,491

 

 

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

 

3


 

SURROZEN, INC.

Condensed Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders’ Equity

(Unaudited)

(In thousands)

 

 

 

Redeemable convertible

 

 

 

 

 

 

 

 

Additional

 

 

Accumulated
other

 

 

 

 

 

Total

 

 

 

preferred stock

 

 

Common stock

 

 

paid-in

 

 

comprehensive

 

 

Accumulated

 

 

stockholders’

 

 

 

Shares

 

 

Amount

 

 

Shares

 

 

Amount

 

 

capital

 

 

loss

 

 

deficit

 

 

equity

 

Balance at December 31, 2020, as previously reported

 

 

95,290

 

 

$

133,097

 

 

 

8,649

 

 

$

1

 

 

$

2,196

 

 

$

 

 

$

(88,001

)

 

$

(85,804

)

Retroactive application of recapitalization

 

 

(95,290

)

 

 

(133,097

)

 

 

9,608

 

 

 

1

 

 

 

133,096

 

 

 

 

 

 

 

 

 

133,097

 

Balance at December 31, 2020, after effect of
   Business Combination

 

 

 

 

 

 

 

 

18,257

 

 

 

2

 

 

 

135,292

 

 

 

 

 

 

(88,001

)

 

 

47,293

 

Exercises of stock options

 

 

 

 

 

 

 

 

76

 

 

 

 

 

 

196

 

 

 

 

 

 

 

 

 

196

 

Restricted stock granted

 

 

 

 

 

 

 

 

123

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Reclassification to liability for early exercised
   stock options

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(120

)

 

 

 

 

 

 

 

 

(120

)

Vesting of early exercised stock options

 

 

 

 

 

 

 

 

 

 

 

 

 

 

30

 

 

 

 

 

 

 

 

 

30

 

Stock-based compensation expense

 

 

 

 

 

 

 

 

 

 

 

 

 

 

475

 

 

 

 

 

 

 

 

 

475

 

Net loss

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(13,022

)

 

 

(13,022

)

Balance at March 31, 2021, after effect of
   Business Combination

 

 

 

 

 

 

 

 

18,456

 

 

 

2

 

 

 

135,873

 

 

 

 

 

 

(101,023

)

 

 

34,852

 

Exercises of stock options

 

 

 

 

 

 

 

 

50

 

 

 

 

 

 

109

 

 

 

 

 

 

 

 

 

109

 

Restricted stock granted

 

 

 

 

 

 

 

 

70

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Restricted stock forfeited